Celgene Ordered To Turn Over Thalomid Price Data

Law360, New York (January 20, 2011, 7:15 PM EST) -- New Jersey-based drugmaker Celgene Corp. must turn over pricing data on its drug Thalomid to Canadian authorities so they can determine if patients are being gouged, Canada's high court ruled Thursday.

The country's Patented Medicine Prices Review Board has jurisdiction to regulate Thalomid prices, even though the drug is not sold directly to Canadian consumers, the Supreme Court of Canada said in a unanimous decision.

Thalomid is a version of the sedative thalidomide used to treat conditions such as leprosy and multiple myeloma, a type of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.